skip to main content, skip to Quick links, or skip to Search

main content

clinical studies

Feline Anti-Nerve Growth Factor Study

orange cat with purple iris flowers in background

Evaluation of the Pain Alleviating Effects of NV-02 in Cats Suffering from Degenerative Joint Disease-Associated Pain


We are seeking participants for a trial of a new biological compound, an antibody, that is being used to treat pain. It is a feline version of a compound being tested for arthritis pain control in humans. The treatment is NOT a non-steroidal anti-inflammatory (NSAID), and will administered once subcutaneously with an expected duration of effect of several weeks.

Description: The purpose of this study is to evaluate the efficacy of NV-02, an antibody to nerve growth factor, for the treatment of osteoarthritis pain in cats. This is a blinded, placebo controlled, pilot study. Thirty-six cats will be recruited into this study. Each cat will be evaluated over an 11-week period for changes in pain and mobility using various owner assessments, activity monitors, kinetic variables and veterinarian-assessed joint pain.

Eligibility:

Cats must satisfy the following criteria:

Cats with the following conditions will be excluded:

Owner obligations:

We need owners of cats to be able to commit to the following:

Study incentives: The study will cover the cost of the examination, hospitalization, blood work and urinalysis, radiographs, and study drug. No other financial incentives are offered for participation. 

 

Contact:
Comparative Pain Research Laboratory at North Carolina State University, College of Veterinary Medicine (919) 513-6854 or email andrea_thomson@ncsu.edu

.